학술논문
COX-2 and NF-KB overexpression is common in pancreatic cancer but does not predict for COX-2 inhibitors activity in combination with gemcitabine and oxaliplatin
Document Type
Article
Author
Source
In: American Journal of Clinical Oncology: Cancer Clinical Trials . (American Journal of Clinical Oncology: Cancer Clinical Trials, October 2007, 30(5):526-530)
Subject
Language
English
ISSN
02773732
1537453X
1537453X